Showing results (141-150 of 1,983) with videos related to
Sort By:
Pageof 199
Oncotarget|April 7, 2016
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experienceShuping Xu, Mayra Ramos-Suzarte, Xianhong Bai, et al.Breast Cancer Research and Treatment|May 13, 2020
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancerFeng Du, Wenmiao Wang, Yongsheng Wang, et al.BMC Cancer|July 22, 2024
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysisMingxia Jiang, Yue Chai, Jiaxuan Liu, et al.Clinical Breast Cancer|January 12, 2019
The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in ChinaBo Lan, Fei Ma, Mei Han, et al.Cancer Biology & Medicine|March 12, 2021
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancerNanlin Hu, Yiran Si, Jian Yue, et al.JAMA Network Open|November 2, 2022
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast CancerHongnan Mo, Xiaoyan Yan, Fang Zhao, et al.Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer|June 13, 2017
Impact of High Altitude on Clinicopathological Features and Prognosis after R0 Resection for Gastric Cancer: A Population-Based Multicenter StudyJiuda Zhao, Feng Du, Yu Zhang, et al.Therapeutic Advances in Medical Oncology|December 24, 2025
Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysisXiaoyan Qian, Xi Chen, Min Xiao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2019
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II StudyFei Ma, Quchang Ouyang, Wei Li, et al.Nature Medicine|July 5, 2024
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trialHongnan Mo, Yongpei Yu, Xiaoying Sun, et al.Pageof 199